Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 98 articles:
HTML format
Text format



Single Articles


    May 2017
  1. JACKSON B, Con D, Ma R, Gorelik A, et al
    Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Scand J Gastroenterol. 2017 May 16:1-6. doi: 10.1080/00365521.2017.1323117.
    PubMed     Text format     Abstract available


  2. KOKKINIDIS DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, et al
    Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 May 14:1-9. doi: 10.1080/00365521.2017.1326163.
    PubMed     Text format     Abstract available


  3. SEO H, Chang K, Lee SH, Song EM, et al
    Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Scand J Gastroenterol. 2017 May 14:1-7. doi: 10.1080/00365521.2017.1323229.
    PubMed     Text format     Abstract available


    April 2017
  4. KWAPISZ L, Gregor J, Chande N, Yan B, et al
    The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 20:1-5. doi: 10.1080/00365521.2017.1315740.
    PubMed     Text format     Abstract available


  5. LEE KE, Jung SA, Yoon H, Park SH, et al
    Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 7:1-7. doi: 10.1080/00365521.2017.1310288.
    PubMed     Text format     Abstract available


    March 2017
  6. JAIME F, Riutort MC, Alvarez-Lobos M, Hoyos-Bachiloglu R, et al
    Solar radiation is inversely associated with inflammatory bowel disease admissions.
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1307444.
    PubMed     Text format     Abstract available


  7. ERIKSSON C, Marsal J, Bergemalm D, Vigren L, et al
    Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1304987.
    PubMed     Text format     Abstract available


  8. WLODARCZYK M, Sobolewska-Wlodarczyk A, Cygankiewicz AI, Jacenik D, et al
    G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2017 Mar 8:1-5. doi: 10.1080/00365521.2017.1298834.
    PubMed     Text format     Abstract available


    January 2017
  9. YE X, Liu S, Hu M, Song Y, et al
    CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and beta-arrestin2 expression.
    Scand J Gastroenterol. 2017 Jan 31:1-10. doi: 10.1080/00365521.2017.1281435.
    PubMed     Text format     Abstract available


  10. JACKSON BD, Con D, Liew D, De Cruz P, et al
    Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jan 27:1-7. doi: 10.1080/00365521.2017.1278785.
    PubMed     Text format     Abstract available


  11. LANDERHOLM K, Abdalla M, Myrelid P, Andersson RE, et al
    Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study.
    Scand J Gastroenterol. 2017 Jan 19:1-5. doi: 10.1080/00365521.2016.1278457.
    PubMed     Text format     Abstract available


    December 2016
  12. GRIMSTAD T, Skoie IM, Doerner J, Isaksen K, et al
    TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Scand J Gastroenterol. 2016 Dec 31:1-5. doi: 10.1080/00365521.2016.1273382.
    PubMed     Text format     Abstract available


  13. CANCADO GG, Vilela EG
    Guillain-Barre syndrome during adalimumab therapy for Crohn s disease: coincidence or consequence?
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  14. LAURELL A, Sjoberg K
    Prebiotics and synbiotics in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  15. BROMS G, Granath F, Stephansson O, Kieler H, et al
    Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Scand J Gastroenterol. 2016;51:1462-1469.
    PubMed     Text format     Abstract available


    November 2016
  16. OLBJORN C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, et al
    Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  17. AMCOFF K, Stridsberg M, Lampinen M, Magnuson A, et al
    Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  18. LANKARANI KB, Sepehrimanesh M, Seghatoleslami F, Hoseini SE, et al
    Autophagy-related protein 7 level in patients with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  19. ZHOU G, Yang W, Yu L, Yu T, et al
    CD99 refers to the activity of inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  20. HUPPERTZ-HAUSS G, Hoivik ML, Jelsness-Jorgensen LP, Opheim R, et al
    Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  21. ENGLUND H, Liden K K, Lind T, Sundstrom T, et al
    Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  22. MOLANDER P, Farkkila M, Kemppainen H, Blomster T, et al
    Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha-blocking agents.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  23. JAKOBSSON GL, Sternegard E, Olen O, Myrelid P, et al
    Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  24. HOGBERG C, Karling P, Rutegard J, Lilja M, et al
    Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  25. MUTHAS D, Reznichenko A, Balendran CA, Bottcher G, et al
    Neutrophils in Ulcerative Colitis: A review of selected biomarkers and their potential therapeutic implications.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  26. FRIGSTAD SO, Hoivik M, Jahnsen J, Dahl SR, et al
    Vitamin D deficiency in inflammatory bowel disease: Prevalence and predictors in a Norwegian outpatient population.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  27. LEHTOLA E, Haapamaki J, Farkkila MA
    Outcome of inflammatory bowel disease patients treated with TNF-alpha inhibitors: two-year follow-up.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  28. KISZKA-KANOWITZ M, Theede K, Mertz-Nielsen A
    Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  29. PROSBERG M, Bendtsen F, Vind I, Petersen AM, et al
    The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  30. JANSEN A, Mandic AD, Bennek E, Frehn L, et al
    Anti-food and anti-microbial IgG subclass antibodies in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  31. HOLT DQ, Strauss BJ, Lau KK, Moore GT, et al
    Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.
    Scand J Gastroenterol. 2016;51:842-7.
    PubMed     Text format     Abstract available


    June 2016
  32. RONNBLOM A, Holmstrom T, Tanghoj H, Karlbom U, et al
    Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  33. DAHLERUP JF, Jacobsen BA, van der Woude J, Bark LA, et al
    High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  34. GRIMSTAD T, Norheim KB, Kvaloy JT, Isaksen K, et al
    Conventional treatment regimens for ulcerative colitis alleviate fatigue - an observational cohort study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  35. ALATRI A, Schoepfer A, Fournier N, Engelberger RP, et al
    Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  36. STIO M, Retico L, Annese V, Bonanomi AG, et al
    Vitamin D regulates the tight-junction protein expression in active ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  37. FOLLIN-ARBELET B, Moum B
    Fluoride: a risk factor for inflammatory bowel disease?
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  38. LARSEN MD, Baldal ME, Nielsen RG, Nielsen J, et al
    The incidence of Crohn's disease and ulcerative colitis since 1995 in Danish children and adolescents <17 years - based on nationwide registry data.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  39. STEFANSDOTTIR J, Bjerrum JT, Nielsen SD
    Non-infectious HIV-associated colitis as a differential diagnosis to ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  40. THORN M, Rorsman F, Ronnblom A, Sangfelt P, et al
    Active cytomegalovirus infection diagnosed by real-time PCR in patients with inflammatory bowel disease: a prospective, controlled observational study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  41. KEIL R, Wasserbauer M, Zadorova Z, Hajer J, et al
    Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  42. NAKANO M, Oka S, Tanaka S, Kunihara S, et al
    Clinical usefulness of transabdominal ultrasonography prior to patency capsule for suspected small-bowel strictures.
    Scand J Gastroenterol. 2016;51:281-7.
    PubMed     Text format     Abstract available


  43. SUNDE ML, Oresland T, Engebreth Faerden A
    Correlation between pouch function and sexual function in patients with IPAA.
    Scand J Gastroenterol. 2016;51:295-303.
    PubMed     Text format     Abstract available


  44. ZHULINA Y, Udumyan R, Tysk C, Montgomery S, et al
    The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Orebro, Sweden 1963-2005.
    Scand J Gastroenterol. 2016;51:304-13.
    PubMed     Text format     Abstract available


    February 2016
  45. KIM JH, Cheon JH, Park Y, Lee HJ, et al
    Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  46. MORITA Y, Bamba S, Takahashi K, Imaeda H, et al
    Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-alpha antibodies in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  47. VEGH Z, Kurti Z, Gonczi L, Golovics PA, et al
    Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  48. THORSEN SU, Jakobsen C, Cohen A, Lundqvist M, et al
    Perinatal vitamin D levels are not associated with later risk of developing pediatric-onset inflammatory bowel disease: a Danish case-cohort study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  49. TAKAHASHI F, Tominaga K, Kanamori A, Takenaka K, et al
    Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  50. NUKI Y, Esaki M, Asano K, Maehata Y, et al
    Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  51. REENAERS C, Pirard C, Vankemseke C, Latour P, et al
    Long-term evolution and predictive factors of mild inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  52. MOUSSATA D, Boschetti G, Stefanescu C, Nancey S, et al
    Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  53. HOLDAM AS, Bager P, Dahlerup JF
    Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  54. ELIGIUS HELLSTROM A, Farkkila M, Kolho KL
    Infliximab-induced skin manifestations in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  55. FASCI-SPURIO F, Pavlidis P, Bjarnason I
    A new form of chronic inflammatory bowel disease associated with chronic liver disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  56. SEIDELIN JB
    Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis.
    Scand J Gastroenterol. 2016;51.
    PubMed     Text format     Abstract available


  57. MAGRO F, Coelho R, Guimaraes LS, Silva M, et al
    Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
    Scand J Gastroenterol. 2016;51:511-2.
    PubMed     Text format    


  58. AGGARWAL D, Limdi JK
    Letter to the editor: anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
    Scand J Gastroenterol. 2016;51:507-8.
    PubMed     Text format    


  59. GARCIA-MEDINA JJ, Pastor-Grau A, del-Rio-Vellosillo M, Zanon-Moreno V, et al
    Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-year follow-up.
    Scand J Gastroenterol. 2016;51:765-6.
    PubMed     Text format    


  60. BAJI P, Gulacsi L, Lovasz BD, Golovics PA, et al
    Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
    Scand J Gastroenterol. 2016;51:22-7.
    PubMed     Text format     Abstract available


  61. FERREIRO-IGLESIAS R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE, et al
    Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Scand J Gastroenterol. 2016;51:442-7.
    PubMed     Text format     Abstract available


  62. PARK SK, Hong M, Ye BD, Kim KJ, et al
    Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:684-91.
    PubMed     Text format     Abstract available


  63. DIGE A, Magnusson MK, Ohman L, Hvas CL, et al
    Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:692-9.
    PubMed     Text format     Abstract available


  64. GABRYEL M, Skrzypczak-Zielinska M, Kucharski MA, Slomski R, et al
    The impact of genetic factors on response to glucocorticoids therapy in IBD.
    Scand J Gastroenterol. 2016;51:654-65.
    PubMed     Text format     Abstract available


  65. HERRANZ BACHILLER MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, et al
    The utility of faecal calprotectin to predict post-operative recurrence in Crohns disease.
    Scand J Gastroenterol. 2016;51:720-6.
    PubMed     Text format     Abstract available


  66. COELHO R, Magro F, Silva M, Macedo G, et al
    Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?
    Scand J Gastroenterol. 2016;51:679-83.
    PubMed     Text format     Abstract available


    December 2015
  67. JELSNESS-JORGENSEN LP, Bernklev T, Hovde O, Prytz Berset I, et al
    Patients' perceptions of quality of care and follow-up in inflammatory bowel disease.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  68. KRISTENSEN V, Malmstrom GH, Skar V, Roseth A, et al
    Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  69. AHMED I, Fayyaz F, Nasir M, Niaz Z, et al
    Extending landscape of volatile metabolites as novel diagnostic biomarkers of inflammatory bowel disease - a review.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  70. KORAL ONAL I, Alizadeh N, Gok Sargin Z
    Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: Disease activity as an influencing factor.
    Scand J Gastroenterol. 2015.
    PubMed     Text format    


  71. MANTZARIS GJ, Papamichael K
    Author's reply to performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor.
    Scand J Gastroenterol. 2015.
    PubMed     Text format    


    September 2015
  72. MIRSEPASI-LAURIDSEN HC, Bachmann Holmetoft U, Ingdam Halkjaer S, Angeliki Krogfelt K, et al
    Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  73. BORTLIK M, Duricova D, Machkova N, Hruba V, et al
    Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  74. PRINCIPI M, Scavo MP, Piscitelli D, Villanacci V, et al
    The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma.
    Scand J Gastroenterol. 2015;50:1002-10.
    PubMed     Text format     Abstract available


    July 2015
  75. PRINCIPI M, Montenegro L, Losurdo G, Zito A, et al
    Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase.
    Scand J Gastroenterol. 2015.
    PubMed     Text format    


  76. FERNANDEZ-SALAZAR L, Munoz F, Barrio J, Munoz C, et al
    Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  77. GUINET-CHARPENTIER C, Champigneulle J, Williet N, Peyrin-Biroulet L, et al
    The association of autoimmune diseases with pediatric ulcerative colitis does not influence its disease course.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  78. SOLBERG IC, Hoivik ML, Cvancarova M, Moum B, et al
    Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study).
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  79. MANTZARIS GJ, Tsironikos D, Tzanetakou X, Grispou E, et al
    The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  80. CLEMMENSEN K, Akrawi N, Stawowy M
    Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  81. GECSE KB, Brandse JF, van Wilpe S, Lowenberg M, et al
    Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Scand J Gastroenterol. 2015;50:841-7.
    PubMed     Text format     Abstract available


    June 2015
  82. LIU G, Lin J, Xie H, Shen B, et al
    Histomorphological features and prognosis of colitis-associated colorectal cancer in patients with primary sclerosing cholangitis.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  83. BJORNSSON S, Tryggvason FThorn, Jonasson JG, Cariglia N, et al
    Incidence of inflammatory bowel disease in Iceland 1995 - 2009. A nationwide population-based study.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  84. BRENNA O, Bruland T, Furnes MW, Granlund AV, et al
    The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  85. VOGELAAR L, van den Berg-Emons R, Bussmann H, Rozenberg R, et al
    Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  86. CAVIGLIA GP, Pellicano R, Astegiano M
    Reply to: Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders.
    Scand J Gastroenterol. 2015;50:623-4.
    PubMed     Text format    


    March 2015
  87. AGILLI M, Aydin FN, Gulcan Kurt Y, Cayci T, et al
    Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders.
    Scand J Gastroenterol. 2015;50:376-7.
    PubMed     Text format    


  88. VEGH Z, Golovics PA, Lovasz BD, Kurti Z, et al
    Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort.
    Scand J Gastroenterol. 2015;50:306-11.
    PubMed     Text format     Abstract available


    February 2015
  89. BOR R, Farkas K, Balint A, Szucs M, et al
    Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease--clinical observations from a tertiary Eastern European center.
    Scand J Gastroenterol. 2015;50:182-7.
    PubMed     Text format     Abstract available


    January 2015
  90. ORESLAND T, Faerden AE
    Surgery in the age of biological treatment.
    Scand J Gastroenterol. 2015;50:121-7.
    PubMed     Text format     Abstract available


  91. RIMOLA J, Panes J, Ordas I
    Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials.
    Scand J Gastroenterol. 2015;50:66-73.
    PubMed     Text format     Abstract available


  92. LATELLA G, Di Gregorio J, Flati V, Rieder F, et al
    Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Scand J Gastroenterol. 2015;50:53-65.
    PubMed     Text format     Abstract available


  93. NAKAMURA S, Sho M, Koyama F, Ueda T, et al
    Erythropoietin attenuates intestinal inflammation and promotes tissue regeneration.
    Scand J Gastroenterol. 2015;50:1094-102.
    PubMed     Text format     Abstract available


    November 2014
  94. CAVIGLIA GP, Pantaleoni S, Touscoz GA, Adriani A, et al
    Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
    Scand J Gastroenterol. 2014.
    PubMed     Text format     Abstract available


    September 2014
  95. HOOG CM, Bark LA, Brostrom O, Sjoqvist U, et al
    Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.
    Scand J Gastroenterol. 2014;49:1084-90.
    PubMed     Text format     Abstract available


    August 2014
  96. JULSGAARD M, Norgaard M, Hvas CL, Grosen A, et al
    Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease.
    Scand J Gastroenterol. 2014;49:958-66.
    PubMed     Text format     Abstract available


  97. IDESTROM M, Rubio CA, Onelov E, Henter JI, et al
    Pediatric Crohn's disease from onset to adulthood: granulomas are associated with an early need for immunomodulation.
    Scand J Gastroenterol. 2014;49:950-7.
    PubMed     Text format     Abstract available


    July 2014
  98. TABIBIAN JH, O'Hara SP, Lindor KD
    Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.
    Scand J Gastroenterol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: